SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Mourits Marian J E)
 

Sökning: WFRF:(Mourits Marian J E) > Nogues Catherine > Oral contraceptive ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00008616naa a2200997 4500
001oai:lup.lub.lu.se:0c73d8cf-dff9-4139-a293-0f815a550bbb
003SwePub
008210201s2021 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:147144570
0247 a https://lup.lub.lu.se/record/0c73d8cf-dff9-4139-a293-0f815a550bbb2 URI
0247 a https://doi.org/10.1016/j.ajog.2021.01.0142 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1471445702 URI
040 a (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Schrijver, Lieske Hu Netherlands Cancer Institute4 aut
2451 0a Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers : an international cohort study
264 1b Elsevier BV,c 2021
520 a BACKGROUND: Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contraceptive preparations (OCPs) use. While the effects of OCPs in the general population are well established (∼50% reduction), the estimated risk reduction in mutation carriers is much less precise due to potential bias and small sample sizes. In addition, only a few studies have examined the associations between duration of use, time since last use, starting age, and calendar year of start with risk of ovarian cancer.OBJECTIVE(S): To investigate in more detail the associations between various characteristics of OCP use and risk of ovarian cancer, to provide health care providers and carriers with better risk estimates.STUDY DESIGN: In this international retrospective study, ovarian cancer risk associations were assessed using OCP data on 3,989 BRCA1 and 2,445 BRCA2 mutation carriers. Age-dependent weighted Cox regression analyses were stratified by study and birth cohort and included breast cancer diagnosis as covariate. To minimize survival bias, analyses were left-truncated at 5 years before baseline questionnaire. Separate analysis were conducted for each of the aspects of OCP use and in a multivariate analysis including all these aspects. In addition, the analysis of duration of OCP use was stratified by recency of use.RESULTS: OCPs were less often used by mutation carriers who were diagnosed with ovarian cancer (Ever use: BRCA1 58.6%, BRCA2 53.5%) than by unaffected carriers (Ever use: BRCA1 88.9%, BRCA2 80.7%. The median duration of use was 7 years for both BRCA1 and BRCA2 carriers who developed ovarian cancer, and 9 and 8 years for ovarian cancer unaffected BRCA1 and BRCA2 carriers, respectively. For BRCA1 mutation carriers univariate analyses showed that both a longer duration of OCP use and more recent use of OCPs were inversely associated with risk of ovarian cancer. However, in multivariate analyses including duration of use, age at first use and time since last use, duration of use proved to be the prominent protective factor (compared with <5 years, 5-9 years HR=0.67;95%CI 0.40-1.12, 10+ years HR=0.37;95%CI 0.19-0.73; ptrend=0.008). The inverse association between duration of use and ovarian cancer risk persisted for more than 15 years (Duration of ≥10 years; BRCA1: <15 years since last use: HR=0.24 95%CI 0.14-0.43, 15+ years since last use: HR 0.56 95%CI 0.18-0.59). Univariate results for BRCA2 mutation carriers were similar, but due to limit sample size inconclusive.CONCLUSION: For BRCA1 mutation carriers, a longer duration of OCP use is associated with a greater reduction of ovarian cancer risk and the protection is long term.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Medicinsk genetik0 (SwePub)301072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Medical Genetics0 (SwePub)301072 hsv//eng
7001 a Antoniou, Antonis Cu University of Cambridge4 aut
7001 a Olsson, Håkanu Skåne University Hospital4 aut0 (Swepub:lu)onk-hol
7001 a Mooij, Thea Mu Netherlands Cancer Institute4 aut
7001 a Roos-Blom, Marie-Joséu Netherlands Cancer Institute4 aut
7001 a Azarang, Leylau Netherlands Cancer Institute4 aut
7001 a Adlard, Julianu Chapel Allerton Hospital4 aut
7001 a Ahmed, Munazau Great Ormond Street Hospital4 aut
7001 a Barrowdale, Daniel4 aut
7001 a Davidson, Rosemarieu Queen Elizabeth University Hospital, Glasgow4 aut
7001 a Donaldson, Alanu Saint Michael's Hospital4 aut
7001 a Eeles, Rosu The Institute of Cancer Research4 aut
7001 a Evans, D Garethu Manchester Metropolitan University4 aut
7001 a Frost, Debra4 aut
7001 a Henderson, Alexu State Institute of Genetic and Regenerative Medicine, Kyiv4 aut
7001 a Izatt, Louiseu City of Hope National Medical Center4 aut
7001 a Ong, Kai-Renu Birmingham Women’s Hospital Healthcare NHS Trust4 aut
7001 a Bonadona, Valérieu Claude Bernard University Lyon 14 aut
7001 a Coupier, Isabelleu Arnaud de Villeneuve Hospital4 aut
7001 a Faivre, Laurenceu Global Innovation Management Institute (GIMI)4 aut
7001 a Fricker, Jean-Pierreu Centre Paul Strauss4 aut
7001 a Gesta, Paulu Centre Hospitalier Georges Renon4 aut
7001 a VAN Engelen, Klaartjeu Fox Chase Cancer Center4 aut
7001 a Jager, Agnesu Erasmus University Medical Center4 aut
7001 a Menko, Fred Hu Netherlands Cancer Institute4 aut
7001 a Mourits, Marian J Eu Hanze University of Applied Sciences4 aut
7001 a Singer, Christian Fu Medical University of Vienna4 aut
7001 a Tan, Yen Yu Medical University of Vienna4 aut
7001 a Foretova, Lenkau Masaryk Memorial Cancer Institute4 aut
7001 a Navratilova, Marieu Masaryk Memorial Cancer Institute4 aut
7001 a Schmutzler, Rita K4 aut
7001 a Ellberg, Carolinau Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Biomarkörer och Epi,Institutionen för kliniska vetenskaper, Lund,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Biomarkers and epidemiology,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)med-elc
7001 a Gerdes, Anne-Marieu Copenhagen University Hospital: Juliane Marie Centre4 aut
7001 a Caldes, Trinidadu Hospital Clinico San Carlos de Madrid4 aut
7001 a Simard, Jacquesu CEA National Genotyping Center (CNG)4 aut
7001 a Olah, Edithu National Institute of Oncology, Budapest4 aut
7001 a Jakubowska, Annau Pomeranian Medical University4 aut
7001 a Rantala, Johannau Karolinska Institutet4 aut
7001 a Osorio, Anau Spanish National Cancer Research Center (CNIO)4 aut
7001 a Hopper, John Lu University of Melbourne4 aut
7001 a Phillips, Kelly-Anneu University of Melbourne4 aut
7001 a Milne, Roger Lu University of Melbourne4 aut
7001 a Terry, Mary Bethu University of Northern British Columbia4 aut
7001 a NoguÈs, Catherineu Institut Paoli-Calmettes4 aut
7001 a Engel, Christophu University Hospital Leipzig4 aut
7001 a Kast, Karin4 aut
7001 a Goldgar, David Eu University of Utah4 aut
7001 a van Leeuwen, Flora Eu Netherlands Cancer Institute4 aut
7001 a Easton, Douglas F4 aut
7001 a Andrieu, Nadineu PSL University4 aut
7001 a Rookus, Matti Au Netherlands Cancer Institute4 aut
7102 a Netherlands Cancer Instituteb University of Cambridge4 org
7102 a EMBRACE Collaborators
7102 a GENEPSO Investigators
7102 a HEBON Investigators
7102 a IBCCS
7730 t American Journal of Obstetrics and Gynecologyd : Elsevier BVg 225:1, s. 1-51q 225:1<1-51x 1097-6868x 0002-9378
8564 u http://dx.doi.org/10.1016/j.ajog.2021.01.014y FULLTEXT
8564 u http://www.ajog.org/article/S0002937821000387/pdf
8564 8u https://lup.lub.lu.se/record/0c73d8cf-dff9-4139-a293-0f815a550bbb
8564 8u https://doi.org/10.1016/j.ajog.2021.01.014
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:147144570

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy